Speciality pharma Tanner has become a distributor of Afrezza outside the US after entering a distribution agreement with MannKind.
Under the deal, Tanner will distribute Afrezza, a rapid-acting inhaled insulin, in US regions the product is not yet registered.
“Al Mann had a vision of making Afrezza available to all people living with diabetes around the world and this agreement helps accelerate that access to Afrezza on a named patient access basis in underserved international markets,” said Michael Castagna, MannKind CEO.
“Our partnership with Tanner Pharma to distribute Afrezza provides us a strong partner with a track record of success in working with physicians, hospitals and ministries of health to provide medicine that is not currently available in their country.”
The distribution will be managed by TannerGAP, a wholly owned subsidiary of Tanner Pharma Group.